ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

ImClone: Waksals To Pay $5 Million To Settle With SEC.

January 28, 2005

PBS Runs Misleading Lung Screening Claim; Reporter and Subject on Mount Sinai Faculty

October 11, 2013

NCI Offers 200 Cell Lines to Scientist

May 6, 1983

Alimta Granted Approval As NSCLC Continuation Therapy

November 25, 2011

McGivney Out at NCCN as Board Cites Management Style, Strategic Direction

January 13, 2012

CMS Issues Coverage Decision For Provenge in Prostate Cancer

July 29, 2011